The other thing on lower back pain is one would have thought that the initial recruitment in the phase 2 trial was of waifs and strays . I bet that in the phase 3 trial they have zeroed in on the profile of patient that they want to recruit and that as a result efficacy could well be a good deal better in the phase 3 trial . On top of that you would have thought that the dd that grunenthal did included a look at the trial including interviews with those conducting the trial . Let's see !
Ann: Mesoblast Phase 3 CLBP Trial Completes Enrollment, page-205
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |